Posted in | News | Nanomedicine | Nanobusiness

Financing Allows NanoString to Accelerate Commercialization of nCounter Analysis System

NanoString Technologies, a life sciences tool company that is commercializing a novel and uniquely user-friendly technology for characterizing and quantifying expression profiles in complex biological samples, announced today that it has closed a $30 million Series C equity financing. This financing, structured in two tranches, will allow NanoString Technologies to accelerate the commercialization of the nCounter™ Analysis System in the research tools and diagnostics arenas.

The round was led by Clarus Ventures, a global life sciences venture capital firm, and was joined by existing investors OVP Venture Partners and Draper Fisher Jurvetson. In connection with the financing, Nicholas Galakatos, co-founder and Managing Director of Clarus Ventures, will join the NanoString Technologies’ Board of Directors.

“We believe that NanoString Technologies has the best-in-class platform for expression profiling. Their uniquely user-friendly technology that does not require sample purification or use of PCR constitutes a breakthrough in the field, as evidenced by the excitement of the scientific community towards their products. We are delighted to be part of the success of this emerging leader,” said Dr. Galakatos.

“Completion of this financing in this tough economic environment is an important validation of the differentiation of the NanoString technology platform, the success with key customers and the insight and determination of Clarus Ventures and our other investors. Our products have received tremendous interest from commercial and clinical researchers in a relatively short amount of time. The new funds will fuel our growth in manufacturing and product development and enhance our commercialization capabilities,” said Wayne Burns, CFO and Acting CEO of NanoString Technologies

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Nanostring Technologies. (2019, March 19). Financing Allows NanoString to Accelerate Commercialization of nCounter Analysis System. AZoNano. Retrieved on February 29, 2024 from https://www.azonano.com/news.aspx?newsID=11953.

  • MLA

    Nanostring Technologies. "Financing Allows NanoString to Accelerate Commercialization of nCounter Analysis System". AZoNano. 29 February 2024. <https://www.azonano.com/news.aspx?newsID=11953>.

  • Chicago

    Nanostring Technologies. "Financing Allows NanoString to Accelerate Commercialization of nCounter Analysis System". AZoNano. https://www.azonano.com/news.aspx?newsID=11953. (accessed February 29, 2024).

  • Harvard

    Nanostring Technologies. 2019. Financing Allows NanoString to Accelerate Commercialization of nCounter Analysis System. AZoNano, viewed 29 February 2024, https://www.azonano.com/news.aspx?newsID=11953.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit
Azthena logo

AZoM.com powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.